name: | Budesonide |
ATC code: | R03BA02 | route: | oral |
n-compartments | 2 |
Budesonide is a synthetic corticosteroid with potent glucocorticoid activity. It is commonly used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis). It is approved and widely used in inhaled, oral, and rectal formulations due to its high first-pass metabolism, which minimizes systemic side effects.
Pharmacokinetic parameters for healthy adult volunteers after single oral administration.
Simeoli, R, et al., & Goffredo, BM (2024). Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia. Pharmaceutics 16(7) –. DOI:10.3390/pharmaceutics16070872 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39065569
Donnelly, R, & Seale, JP (2001). Clinical pharmacokinetics of inhaled budesonide. Clinical pharmacokinetics 40(6) 427–440. DOI:10.2165/00003088-200140060-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11475468
Abdalla, MI, & Herfarth, H (2016). Budesonide for the treatment of ulcerative colitis. Expert opinion on pharmacotherapy 17(11) 1549–1559. DOI:10.1080/14656566.2016.1183648 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27157244